Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Pergoveris in Healthy Japanese and Caucasian Females
NCT07269327Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of luteinizing hormone in infertility (2 arms), sponsored by Merck KGaA. Primary endpoints: Baseline-Adjusted Area Under the Serum Concentration-Time Curve from Time Zero to Last Quantifiable Sampling Time and Baseline-Adjusted Maximum Observed Serum Concentration. Started Nov 2025; status: completed.
02
Drugs
luteinizing hormone
03
Conditions
infertility
Beyond the preview
Go deeper on NCT07269327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269327.